KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Operating Expenses (2019 - 2026)

GoodRx Holdings' Operating Expenses history spans 7 years, with the latest figure at $172.1 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 4.6% to $172.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $709.4 million, a 2.36% decrease, with the full-year FY2025 number at $709.4 million, down 2.36% from a year prior.
  • Operating Expenses hit $172.1 million in Q4 2025 for GoodRx Holdings, down from $181.4 million in the prior quarter.
  • Over the last five years, Operating Expenses for GDRX hit a ceiling of $218.3 million in Q3 2023 and a floor of $165.4 million in Q1 2021.
  • Historically, Operating Expenses has averaged $185.5 million across 5 years, with a median of $181.1 million in 2024.
  • The widest YoY moves for Operating Expenses: up 117.0% in 2021, down 55.52% in 2021.
  • Tracing GDRX's Operating Expenses over 5 years: stood at $201.5 million in 2021, then dropped by 9.49% to $182.4 million in 2022, then increased by 17.85% to $214.9 million in 2023, then fell by 16.07% to $180.4 million in 2024, then decreased by 4.6% to $172.1 million in 2025.
  • Business Quant data shows Operating Expenses for GDRX at $172.1 million in Q4 2025, $181.4 million in Q3 2025, and $176.3 million in Q2 2025.